Immune-Onc Therapeutics Announces SITC Poster Presentation on IO-108, a Novel Cancer Immunotherapy Targeting LILRB2 (ILT4) for Solid Tumors
PALO ALTO, CA, October 15, 2020 -- Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage cancer immunotherapy company, today announced a poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 35th annual meeting, November 10-15, 2020, which will be held virtually.
The presentation of Abstract 686, titled “Preclinical Characterization of a Novel Therapeutic Antibody Targeting LILRB2”, will highlight preclinical data evaluating the company’s IND candidate IO-108, an antagonistic antibody of LILRB2 (also known as ILT4), for the treatment of solid tumors.
“There is a growing recognition of the importance of LILRB2 as a myeloid checkpoint target in cancer immunotherapy,” said Charlene Liao, Ph.D., co-founder and CEO of Immune-Onc. “Immune-Onc is developing immunotherapies targeting LILRB2 and other leukocyte immunoglobulin-like receptors that hinder the immune response to cancer. The preclinical data being shared at the upcoming SITC meeting demonstrate the potential to enhance anti-tumor immunity by antagonizing LILRB2.”
Even numbered posters will be presented on Thursday, Nov. 12, from 4:50-5:20 p.m. EST and Saturday, Nov. 14, from 1-1:30 p.m. EST.
ABOUT IMMUNE-ONC THERAPEUTICS
Immune-Onc Therapeutics, Inc. (“Immune-Onc”) is a clinical-stage cancer immunotherapy company dedicated to the discovery and development of novel biologic treatments for cancer patients. Headquartered in Palo Alto, California, Immune-Onc has assembled a diverse team with deep expertise in drug development and proven track records of success at leading biotechnology companies.
The company aims to translate unique scientific insights in myeloid biology and immune inhibitory receptors to discover and develop first-in-class biotherapeutics that target novel immunosuppressive myeloid checkpoints. Immune-Onc has a promising pipeline built upon strategic collaborations and cutting-edge research from The University of Texas, Albert Einstein College of Medicine, and Memorial Sloan Kettering Cancer Center.
Immune-Onc’s lead program IO-202, a first-in-class antibody targeting LILRB4 (also known as ILT3), is being developed to treat acute myeloid leukemia and other cancers. IO-202 is the first T-cell activator for AML. In September 2020, Immune-Onc initiated a Phase I trial evaluating IO-202 in blood cancers, AML and CMML. The company plans to evaluate IO-202 in other blood cancers and solid tumors in the future. Immune-Onc’s preclinical pipeline includes IO-108, an antibody targeting LILRB2 (also known as ILT4) in IND-enabling studies, an anti-LAIR1 antibody, and multiple undisclosed programs for solid tumors and hematologic malignancies. For more information, please visit www.immune-onc.com and follow us on Twitter and LinkedIn.
MEDIA CONTACT
Tara Cooper
The Grace Communication Group
media@immuneonc.com
650-303-7306
